Bronchogen vs Chonluten
Moderate Research vs Moderate Research
synergistic Related respiratory bioregulators; complementary mechanisms.
Molecular Data
Bronchogen Chonluten
Weight 432 Da 319 Da
Half-life Minutes (short peptide); effects persist via epigenetic changes Minutes (short peptide); effects persist via epigenetic changes
Chain 4 amino acids 3 amino acids
Type Tetrapeptide bioregulator Tripeptide bioregulator
Key Benefits
Bronchogen
01 Supports bronchial tissue function
02 Regulates protein synthesis in lungs
03 Targets bronchopulmonary system
04 Maintains respiratory epithelium
05 Part of Khavinson bioregulator family
06 Epigenetic mechanism of action
07 Tissue-specific targeting
08 Well-tolerated in research
Chonluten
01 Normalizes respiratory system function
02 Regulates protein synthesis in lung tissue
03 Inhibits inflammatory TNF production
04 Restores lung alveolar tissues
05 Maintains bronchial mucous membranes
06 Supports antioxidant gene expression
07 May slow cell aging (geroprotective)
08 Modulates mucosal function
Dosing Protocols
Bronchogen
10-20 mg oral or 10 mg injectable / Daily for 10-20 days per cycle
Research protocol 10 mg Daily for 10 days
Chonluten
10-20 mg daily / Once daily for 10-20 consecutive days
Research protocol 10 mg Daily for 10 days
Side Effects
Bronchogen
Generally well-tolerated
Minimal side effects reported
Chonluten
Generally well-tolerated
Minimal side effects reported
Contraindications
Active respiratory emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Active respiratory emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
Bronchogen Chonluten
Status Moderate Research Moderate Research
References 3 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.